Effect of Intensive Blood Pressure Lowering on Kidney Tubule Injury : Findings From the ACCORD Trial Study Participants
Copyright © 2018 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved..
RATIONALE & OBJECTIVE: Random assignment to intensive blood pressure (BP) lowering (systolic BP<120mmHg) compared to a less intensive BP target (systolic BP<140mmHg) in the Action to Control Cardiovascular Risk in Diabetes BP (ACCORD-BP) trial resulted in a more rapid decline in estimated glomerular filtration rate (eGFR). Whether this reflects hemodynamic effects or intrinsic kidney damage is unknown.
STUDY DESIGN: Longitudinal analysis of a subgroup of clinical trial participants.
SETTINGS & PARTICIPANTS: A subgroup of 529 participants in ACCORD-BP.
EXPOSURES: Urine biomarkers of tubular injury (kidney injury molecule 1, interleukin 18 [IL-18]), repair (human cartilage glycoprotein 39 [YKL-40]), and inflammation (monocyte chemoattractant protein 1) at baseline and year 2.
OUTCOMES: Changes in eGFR from baseline to 2 years.
ANALYTICAL APPROACH: We compared changes in biomarker levels and eGFRs across participants treated to an intensive versus less intensive BP goal using analysis of covariance.
RESULTS: Of 529 participants, 260 had been randomly assigned to the intensive and 269 to the standard BP arm. Mean age was 62±6.5 years and eGFR was 90mL/min/1.73m2. Baseline clinical characteristics, eGFRs, urinary albumin-creatinine ratios (ACRs), and urinary biomarker levels were similar across BP treatment groups. Compared to less intensive BP treatment, eGFR was 9.2mL/min/1.73m2 lower in the intensive BP treatment group at year 2. Despite the eGFR reduction, within this treatment group, ACR was 30% lower and 4 urinary biomarker levels were unchanged or lower at year 2. Also within this group, participants with the largest declines in eGFRs had greater reductions in urinary IL-18 and YKL-40 levels. In a subgroup analysis of participants developing incident chronic kidney disease (sustained 30% decline and eGFR<60mL/min/1.73m2; n=77), neither ACR nor 4 biomarker levels increased in the intensive treatment group, whereas the level of 1 biomarker, IL-18, increased in the less intensive treatment group.
LIMITATIONS: Few participants with advanced baseline chronic kidney disease. Comparisons across treatment groups do not represent comparisons of treatment arms created solely through randomization.
CONCLUSIONS: Among a subset of ACCORD-BP trial participants, intensive BP control was associated with reductions in eGFRs, but not with an increase in injury marker levels. These findings support that eGFR decline observed with intensive BP goals in ACCORD participants may predominantly reflect hemodynamic alterations.
| Errataetall: |
CommentIn: Am J Kidney Dis. 2019 Jan;73(1):4-7. - PMID 30424915 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
American journal of kidney diseases : the official journal of the National Kidney Foundation - 73(2019), 1 vom: 01. Jan., Seite 31-38 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nadkarni, Girish N [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.12.2019 Date Revised 09.01.2021 published: Print-Electronic CommentIn: Am J Kidney Dis. 2019 Jan;73(1):4-7. - PMID 30424915 Citation Status MEDLINE |
|---|
| doi: |
10.1053/j.ajkd.2018.07.016 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM289263689 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM289263689 | ||
| 003 | DE-627 | ||
| 005 | 20231225062153.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1053/j.ajkd.2018.07.016 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0964.xml |
| 035 | |a (DE-627)NLM289263689 | ||
| 035 | |a (NLM)30291011 | ||
| 035 | |a (PII)S0272-6386(18)30880-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nadkarni, Girish N |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of Intensive Blood Pressure Lowering on Kidney Tubule Injury |b Findings From the ACCORD Trial Study Participants |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.12.2019 | ||
| 500 | |a Date Revised 09.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Am J Kidney Dis. 2019 Jan;73(1):4-7. - PMID 30424915 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a RATIONALE & OBJECTIVE: Random assignment to intensive blood pressure (BP) lowering (systolic BP<120mmHg) compared to a less intensive BP target (systolic BP<140mmHg) in the Action to Control Cardiovascular Risk in Diabetes BP (ACCORD-BP) trial resulted in a more rapid decline in estimated glomerular filtration rate (eGFR). Whether this reflects hemodynamic effects or intrinsic kidney damage is unknown | ||
| 520 | |a STUDY DESIGN: Longitudinal analysis of a subgroup of clinical trial participants | ||
| 520 | |a SETTINGS & PARTICIPANTS: A subgroup of 529 participants in ACCORD-BP | ||
| 520 | |a EXPOSURES: Urine biomarkers of tubular injury (kidney injury molecule 1, interleukin 18 [IL-18]), repair (human cartilage glycoprotein 39 [YKL-40]), and inflammation (monocyte chemoattractant protein 1) at baseline and year 2 | ||
| 520 | |a OUTCOMES: Changes in eGFR from baseline to 2 years | ||
| 520 | |a ANALYTICAL APPROACH: We compared changes in biomarker levels and eGFRs across participants treated to an intensive versus less intensive BP goal using analysis of covariance | ||
| 520 | |a RESULTS: Of 529 participants, 260 had been randomly assigned to the intensive and 269 to the standard BP arm. Mean age was 62±6.5 years and eGFR was 90mL/min/1.73m2. Baseline clinical characteristics, eGFRs, urinary albumin-creatinine ratios (ACRs), and urinary biomarker levels were similar across BP treatment groups. Compared to less intensive BP treatment, eGFR was 9.2mL/min/1.73m2 lower in the intensive BP treatment group at year 2. Despite the eGFR reduction, within this treatment group, ACR was 30% lower and 4 urinary biomarker levels were unchanged or lower at year 2. Also within this group, participants with the largest declines in eGFRs had greater reductions in urinary IL-18 and YKL-40 levels. In a subgroup analysis of participants developing incident chronic kidney disease (sustained 30% decline and eGFR<60mL/min/1.73m2; n=77), neither ACR nor 4 biomarker levels increased in the intensive treatment group, whereas the level of 1 biomarker, IL-18, increased in the less intensive treatment group | ||
| 520 | |a LIMITATIONS: Few participants with advanced baseline chronic kidney disease. Comparisons across treatment groups do not represent comparisons of treatment arms created solely through randomization | ||
| 520 | |a CONCLUSIONS: Among a subset of ACCORD-BP trial participants, intensive BP control was associated with reductions in eGFRs, but not with an increase in injury marker levels. These findings support that eGFR decline observed with intensive BP goals in ACCORD participants may predominantly reflect hemodynamic alterations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
| 650 | 4 | |a CKD progression | |
| 650 | 4 | |a Chronic kidney disease (CKD) | |
| 650 | 4 | |a blood pressure (BP) | |
| 650 | 4 | |a eGFR decline | |
| 650 | 4 | |a estimated glomerular filtration rate (eGFR) | |
| 650 | 4 | |a hemodynamics | |
| 650 | 4 | |a hypertension | |
| 650 | 4 | |a intensive BP control | |
| 650 | 4 | |a kidney tubule | |
| 650 | 4 | |a renal perfusion | |
| 650 | 4 | |a tubular injury | |
| 650 | 4 | |a urinary biomarkers | |
| 650 | 4 | |a urine | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Chauhan, Kinsuk |e verfasserin |4 aut | |
| 700 | 1 | |a Rao, Veena |e verfasserin |4 aut | |
| 700 | 1 | |a Ix, Joachim H |e verfasserin |4 aut | |
| 700 | 1 | |a Shlipak, Michael G |e verfasserin |4 aut | |
| 700 | 1 | |a Parikh, Chirag R |e verfasserin |4 aut | |
| 700 | 1 | |a Coca, Steven G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of kidney diseases : the official journal of the National Kidney Foundation |d 1982 |g 73(2019), 1 vom: 01. Jan., Seite 31-38 |w (DE-627)NLM012600814 |x 1523-6838 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2019 |g number:1 |g day:01 |g month:01 |g pages:31-38 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1053/j.ajkd.2018.07.016 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2019 |e 1 |b 01 |c 01 |h 31-38 | ||